Page last updated: 2024-12-11

ono 8711

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ONO 8711: a prostaglandin E receptor EP1 antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9824507
SCHEMBL ID1983864
MeSH IDM0338067

Synonyms (16)

Synonym
(z)-6-[(7s,8r)-7-[[(4-chloro-2-methylphenyl)sulfonylamino]methyl]-8-bicyclo[2.2.2]octanyl]hex-5-enoic acid
gtpl1920
6-((2s,3s)-3-(4-chloro-2-methylphenysulfonylaminomethyl)-bicyclo(2.2.2)octan-2-yl)-5z-hexenoic acid
ono 8711
ono8711
ono-8711
BCP9001027
216158-34-8
SCHEMBL1983864
6-[(2r,3s)-3-[[[(4-chloro-2-methylphenyl)sulfonyl]amino]methyl]bicyclo[2.2.2]oct-2-yl]-5z-hexenoic acid
Q27088189
5-hexenoic acid, 6-((2r,3s)-3-((((4-chloro-2-methylphenyl)sulfonyl)amino)methyl)bicyclo(2.2.2)oct-2-yl)-, (5z)-
(z)-6-[(2r,3s)-3-[[(4-chloro-2-methylphenyl)sulfonylamino]methyl]-2-bicyclo[2.2.2]octanyl]hex-5-enoic acid
HY-12182
CS-0003141
AKOS040744985

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" At 20 weeks after the last dosing of PhIP, all animals were killed and complete autopsy was made."( Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development.
Kawamori, T; Kondo, K; Maruyama, T; Nakatsugi, S; Ohuchida, S; Sugimura, T; Uchiya, N; Wakabayashi, K; Watanabe, K; Yamamoto, H, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1346408Human EP1 receptor (Prostanoid receptors)1999Cancer research, Oct-15, Volume: 59, Issue:20
Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis.
AID1346372Mouse EP1 receptor (Prostanoid receptors)1999Cancer research, Oct-15, Volume: 59, Issue:20
Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis.
AID1346422Human TP receptor (Prostanoid receptors)1999Cancer research, Oct-15, Volume: 59, Issue:20
Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis.
AID1346336Mouse EP3 receptor (Prostanoid receptors)2000Cancer letters, Aug-01, Volume: 156, Issue:1
Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.13)18.2507
2000's20 (62.50)29.6817
2010's11 (34.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.04 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]